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Prostate cancer is one of the most frequent cancers in men. Although several treat-
ment options exist, their clinical effectiveness is still not satisfactory. One the pos-
sible reason of such situation might be the presence of myeloid-derived suppressor 
cells (MDSC) and their pro-tumorigenic activity. MDSC possess immunosuppres-
sive ability and in many studies were shown to support tumor development and 
progression. In this study we addressed the question whether commonly used ther-
apies of prostate cancer affect the level of MDSC populations in the patients’ blood. 
We compared the level of granulocytic (Gr-MDSC), monocytic (Mo-MDSC) and 
early stage MDSC (eMDSC) in the blood of patients at different clinical stage 
and different tumor grading scores, who underwent either surgery or hormonal 
therapy alone or were given a combined treatment, including e.g. radiotherapy. 
The obtained results showed that the level of Gr-MDSC was significantly lower in 
all treated patients comparing to untreated group. On the other hand, surgery or 
hormonal therapy alone did not affect the level of Mo-MDSC. These results were 
independent of the PSA level, the tumor grading and clinical stage of the patients. 
In conclusion, we suggest that Mo-MDSC should be considered as a potential ther-
apy target in the course of prostate cancer treatment to enhance its anti-tumor 
effectiveness.
Key words: prostate cancer (PC), myeloid-derived suppressor cells (MDSC), flow 
cytometry, prostate specific antigen (PSA). 
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Introduction
Prostate cancer (PC) is the second most frequently 
diagnosed cancer in men and the fifth leading cause 
of cancer death worldwide [1]. Economic develop-
ment, increased consumption of animal fat, obesity 
and lack of physical activity have been considered as 
modifiable risk factors of this type of cancer [2, 3]. 
On the other hand, many factors including improved 
treatment and early detection of PC, e.g. thanks 
to preventive programs, reduce the death rate [2]. 
In the early 1990s, soon after the introduction 
of a prostate-specific antigen (PSA) testing to 
the routine diagnostic procedure, the rapid growth 
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of incidence of prostate cancer was observed [2, 4]. 
Since then, due to frequent false positive results 
of PSA test and severe side effects of subsequent un-
necessary treatment, the usefulness of routine PSA 
screening is a matter of debate [5, 6]. Therefore, ef-
forts are undertaken to discover new more reliable 
tests, such as urine-based, that could play a major 
role in a primary screening [7]. In the middle of 20th 
century it was noticed that prostate cancer had been 
influenced by androgens and could be inhibited by 
elimination of these hormones, either through cas-
tration or neutralization of androgen activity by es-
trogen injections [8]. However, despite the low level 
of androgens, the so called castration-resistant pros-
tate cancer still has an ability for progression. With 
many possibilities for prostate cancer treatment, 
including watchful waiting, surgery, radio-, chemo- 
and biological therapy [9,10], there is still a lack 
of satisfactory results, as tumor resistance to the ap-
plied treatment develops quite often. Recent studies 
indicate that the failure of prostate cancer treatment 
may be due to the myeloid-derived suppressor cells 
(MDSC), which were shown to support tumor devel-
opment and recurrence [11].
MDSC compose a heterogeneous population 
of myeloid cells at different stage of differentiation, 
which regulate the immune response [12]. Neverthe-
less, under chronic inflammatory conditions, infec-
tions or cancer, due to the inhibition of myeloid cell 
differentiation the level of MDSC is elevated [13]. 
Numerous studies present evidence that inflammato-
ry factors produced by tumor may induce generation 
of MDSC and/or increase their activity [14]. Despite 
high heterogeneity, MDSC are frequently distin-
guished as granulocytic (Gr-MDSC) and monocytic 
(Mo-MDSC) [12]. Recently, a population of so called 
early stage MDSC (eMDSC) has also been identi-
fied [15]. In humans, minimal phenotype character-
istics define Gr-MDSC as CD11b+ CD14– CD15+, 
while Mo-MDSC as CD11b+ CD14+ HLA-DR–/
lo CD15–. Population of eMDSC is recognized as 
CD11b+ CD14– CD15– [16]. Both Mo-MDSC and 
Gr-MDSC effectively inhibit T lymphocytes activity, 
although using different mechanisms, whereas func-
tion of eMDSC is still not clear [16, 17, 18]. Gr-MDSC 
preferentially express arginase – 1 (ARG1) and NA-
DPH oxidase. Hence, Gr-MDSC show a higher 
production of reactive oxygen species (ROS) when 
compared to Mo-MDSC, which, on the other hand, 
comparing to Gr-MDSC display increased expression 
of inducible nitric oxide synthase (NOS2) and NO 
production [19]. MDSC could also induce T regu-
latory cells, which are often correlated with cancer 
progression [20].
Here, we asked whether commonly used therapies 
of prostate cancer affect the level of MDSC popula-
tions in peripheral blood of patients.
Material and methods
Patients
Patients with PC were recruited from the Maria 
Skłodowska-Curie Cancer Center in Krakow. 43 PC 
patients (treated or untreated) and 23 healthy age-
matched controls (CTR) (mean age 67.64 ±9.08 
PC vs. 69.6 ±6.31 CTR; p = 0.062) were enrolled 
into the study. As the PC group was heterogeneous 
in respect to the treatment options, it was further 
divided into four following subgroups: I – patients 
before treatment – 21, II – patients after a surgical 
removal of the tumor – 7, III – patients who received 
combined therapy (more than one type of treatment 
chemo-/radio-/ hormonal therapy/ surgery) – 9 and 
IV – patients with hormonal therapy alone  – 6. PSA 
level (ng/ml), the Gleason scoring and clinical stag-
ing were performed routinely. The Gleason score as-
signs two most common histological patterns from 
1 for highly differentiated to 5 for low differentiated 
cancers, with summary score ranging from 2 to 10. 
Further characterization of the patients’ group is pre-
sented in Table I, while their classification according 
to the American Joint Committee on Cancer (AJCC) 
is presented in Table II [21]. All patients provided 
a signed informed consent and the study proto-
col was approved by the local bioethics committee 
of the Regional Board of Medical Doctors in Krakow 
(no. 6/KBL/OIL/2014).
Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) were 
isolated from blood samples obtained from prostate 
cancer patients and healthy controls by standard den-
sity gradient centrifugation. Blood was collected into 
BD CPTTM mononuclear cell preparation tubes con-
taining sodium citrate and Ficoll™ Hypaque™ Solu-
tion (Vacutainer System; Becton Dickinson, San Jose, 
CA) and the tubes were centrifuged at 1400×g for 
15 min at room temperature. PBMCs were collected 
from the interphase, washed in PBS, resuspended in 
0.5 ml of PBS and used for further analysis.
Flow cytometry analysis of Gr-MDSC,  
Mo-MDSC and eMDSC
For Gr-MDSC and Mo-MDSC analysis, PBMC 
(app. 1 × 106 cells/100 µl) were stained with follow-
ing monoclonal antibodies (mAbs): anti-LIN-AF700 
(anti-CD3 clone UCTHT1, anti-CD19 clone HIB19, 
anti-CD56 clone B159), anti-CD33– PE (clone 
P67,6), anti-HLA-DR-PerCp (clone L243), anti-
CD11b-BV510 (clone ICR F44), anti-CD14-FITC 
(MɸP9), anti-CD15-PE-Cy7 (clone HI98) (BD 
Biosciences; San Jose, CA) for 20 min in 4°C. After 
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Table I. Characterisation of the patients group. The patients in the stage group were qualified according to the AJCC 
guidelines (Table II). The grade group depends on Gleason score (summary of the two most common histological patterns 
of the tumor with scores ranging from 1 for highly differentiated to 5 for low differentiated cancer)
PrOsTaTe cancer PaTienTs all befOre TreaTmenT
43 21
PSA level (ng/ml) 33.67 ±35.02 30.14 ±34.44
Stage groups
2b 11 6
2c 2 2
3a 7 1
3b 17 9
4a 5 3
4b 2 1
Grade groups
1 (6 = 3 + 3) 1 -
2 (7 = 3 + 4) 14 7
3 (7 = 4 + 3) 15 6
4 (8 = 3 + 5; 4 + 4) 7 4
5 (9 – 10 = 4 + 5; 5 + 4; 5 + 5) 6 3
Table II. Clinical classification of the patients with prostate 
cancer according to the AJCC guidelines [21]. The TNM 
staging system describes the size and extent of the primary 
tumor (T), metastasis to the local lymph nodes (N), and 
distant metastasis (M); × means any result
T n m Psa  
(ng/ml)
grade 
grOuP
sTage 
grOuP
cT1a-c N0 M0 < 10 1 I
cT2a N0 M0 < 10 1 I
pT2 N0 M0 < 10 1 I
cT1a-c N0 M0 ≥ 10 < 20 1 IIa
cT2a N0 M0 ≥ 10 < 20 1 IIa
pT2 N0 M0 ≥ 10 < 20 1 IIa
cT2b-c N0 M0 < 20 1 IIa
T1-2 N0 M0 < 20 2 IIb
T1-2 N0 M0 < 20 3 IIc
T1-2 N0 M0 < 20 4 IIc
T1-2 N0 M0 ≥ 20 1-4 IIIa
T3-4 N0 M0 × 1-4 IIIb
Tx N0 M0 × 5 IIIc
Tx N1 M0 × × IVa
Tx Nx M1 × × IVb
incubation, cells were washed twice in PBS, suspend-
ed in 0.2 ml PBS and analyzed using FACSCanto flow 
cytometer (Becton Dickinson, CA, USA) and FACS-
Diva software (BD). The Gr-MDSC, Mo-MDSC and 
eMDSC subsets were characterized as LIN- CD33+ 
HLA-DR– CD11b+ CD14– CD15+, LIN– 
CD33+ HLA-DR- CD11b+ CD14+ CD15– and 
LIN- CD33+ HLA-DR– CD11b+ CD14- CD15- 
respectively, and presented as a percent of nucleated 
cells (%NC) (Fig. 1). In order to determine the level 
of non-specific staining and cellular autofluorescence, 
the fluorescence minus one (FMO) control samples 
were prepared and analyzed in parallel.
Statistical analysis
Statistical analysis was performed using the PRISM 
GraphPad 5 package (GraphPad Software Inc., San 
Diego, CA, USA). Obtained data were analyzed us-
ing Mann Whitney test after Shapiro-Wilk normal-
ity test or one-way analysis of variance (ANOVA) 
with Newman-Keuls Multiple Comparison Test as 
post hoc test. All data are expressed as mean ± SD. 
P < 0.05 was considered statistically significant. 
Results
In the present study we aimed to evaluate the lev-
el of MDSC populations in the blood of prostate 
cancer patients, depending on the PSA level, tumor 
grading, clinical stage of the patients and treatment 
option they received. For this purpose we used flow 
49
Myeloid derived-suppressor cells and prostate cancer
cytometry analysis of peripheral blood leukocytes. 
The calculated mean percent value of Gr-MDSC 
in the whole group of PC patients was statistically 
higher when compared to control healthy individ-
uals (2.53 ±2.81 in PC vs. 0.30  ±0.33 in CTR; 
p < 0.0001) (Fig. 2), as was the level of Mo-MDSC 
(10.67 ±8.15 in PC vs. 1.17 ±0.94 in CTR; 
p < 0.0001) (Fig. 2). In case of eMDSC, no statis-
tically significant difference between patients and 
healthy controls was observed (data not shown). Al-
though the usefulness of monitoring the PSA level is 
a matter of debate, it is still generally considered as 
a biomarker of the disease state. With this in mind, 
in the next step we asked if there is any correlation 
between the MDSC percentages and related PSA lev-
els. We have shown such a correlation for Mo-MDSC 
(Pearson r = 0.31; p = 0.047) but not for Gr-MDSC 
(Fig. 3). In this context, it was interesting to find out 
whether the level of MDSC correlates with the tu-
mor grading according to Gleason scale or clinical 
staging of the patients. Therefore, considering Glea-
son score we divided our patients into four groups 
(according to the AJCC classification) and compared 
them with the level of Mo-MDSC and Gr-MDSC in 
peripheral blood, respectively. The obtained results 
indicated that regardless of Gleason score, the pros-
tate cancer patients presented higher level of both 
Gr-MDSC and Mo-MDSC populations (Fig. 4) in 
comparison to healthy individuals. Moreover there 
was no significant differences in the level of Gr-MD-
SC and Mo-MDSC between the groups of patients 
(Fig. 4). These aspects were also analyzed in respect 
to the clinical stage of the patients, taking into ac-
count the PSA level, TNM classification and Gleason 
score (grade group) (Table II) [21]. In this case, due 
to the small number of patients in the groups IIb and 
IIc, IIIa, and IIIb, and IVa and IVb they were includ-
ed to group II, III and IV, respectively. In such analy-
sis, the level of both populations of MDSC was higher 
Fig. 1. Gating strategy for flow cytometry identification of Gr-MDSC, Mo-MDSC, eMDSC in peripheral blood of pros-
tate cancer patients
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in cancer patients in comparison to healthy controls, 
despite the disease stage (Fig. 5).
In the next step of analysis, a logical consequence 
was to evaluate the level of Gr-MDSC and Mo-MD-
SC in the patients’ blood in respect to the mode 
of therapy they received. For this purpose the group 
of patients was subdivided into four groups, including 
patients before treatment, receiving surgery or hor-
monal therapy alone or receiving a combined ther-
apy. The obtained data show that the mean propor-
tion of Gr-MDSC in peripheral blood of patients was 
significantly higher in the group before treatment, 
comparing to healthy controls (3.82 ±3.23 vs. 0.30 
±0.33; p < 0.001) (Fig. 6), whereas the patients 
with formerly implemented therapy had reduced per-
centage of Gr-MDSC, reaching the level detected in 
the blood of healthy controls. In the group of patients 
after surgery (II group) and hormonal therapy (IV 
group) the results did not differ significantly (1.81 
±1.73 vs. 1.6 ±2.15) (Fig. 6), while in patients re-
ceiving combined therapy the level of Gr-MDSC was 
the lowest (0.69 ±0.70). In relation to Mo-MDSC, 
their level in the group of patients before treatment 
(I) and patients treated with hormonal therapy (IV 
group) was significantly higher than in the control 
group (15.40 ±10.94 in I group, 17.37 ±5.06 in 
IV group vs. 1.17 ±0.94 CTR; p < 0.0001 for both) 
(Fig. 6) and the highest level was observed in patients 
after surgery (15.40 ±10.94). Moreover, again, pa-
tients after combined therapy showed the lowest lev-
el of Mo-MDSC (5.50 ±5.40) (Fig. 6).
When comparing the PSA level with the treatment 
option the patients received, we found that the pa-
tients after surgical removal of the tumor or those 
receiving a combined therapy presented the lowest 
level of PSA (14.00±11.16 and 20.44±17.45, re-
spectively), whereas the patients before any treatment 
had medium values of this marker (30.14±34.44). 
On the other hand, patients after hormonal thera-
py presented the highest PSA level (77.00 ±40.03; 
p < 0.01) (Fig. 6). 
Discussion 
Our study documents increased level of Gr-MDSC 
and Mo-MDSC in the prostate cancer patients’ 
Fig. 2. Level of Gr-MDSCs (A) and Mo-MDSCs (B) in healthy control subjects and prostate cancer patients (% NC – % 
of nucleated cells)
Fig. 3. Correlation between PSA level (ng/ml) and Gr-MDSC (A) and Mo-MDSC (B) percentage (% NC – % of nucleated cells)
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Fig. 4. Gr-MDSC (A) Mo-MDSC (B) PSA level (C) in healthy control subjects (CTR) and prostate cancer patients divided 
into four groups according to Gleason score. PSA normal level is indicated
Fig. 5. Gr-MDSC (A) Mo-MDSC (B) PSA level (C) in healthy control subjects and prostate cancer patients divided into 
three groups according to the AJCC guidelines. PSA normal level is indicated
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blood, corroborating the previous reports [22, 23]. 
However, to the best of our knowledge the assess-
ment of the level of MDSC populations in the blood 
of prostate cancer patients in respect to different 
forms of their treatment has not been performed so 
far. In our report we did not show any difference in 
the eMDSC level between patients and healthy in-
dividuals but data on this specific MDSC subset in 
prostate cancer is still missing in the literature. Al-
though, in many types of cancer, Mo-MDSC main-
ly settle the tumor whereas Gr-MDSC prevail in 
the blood [24], in case of prostate cancer this rela-
tion is quite opposite, as higher level of Mo-MDSC 
than Gr-MDSC has been detected in peripheral 
blood [25]. This observation has been confirmed in 
our study. One of the first studies on MDSC in pros-
tate cancer indicated that the level of Mo-MDSC in 
the blood of patients was positively correlated with 
the PSA level [26]. Our results corroborate this ob-
servation, however it is worth noting that the PSA 
level did correlate neither with the tumor grading 
nor with the clinical stage of the patients. It was al-
ready shown that the level of Mo-MDSC in peripheral 
blood of patients with prostate cancer increases with 
the progression of the tumor [27]. Knowing the role 
of MDSC in cancer development and progression one 
would expect that the treatment will reduce the level 
of these cells [22, 23]. Our results suggest that this is 
a case only for Gr-MDSC. Despite the treatment op-
tion the patients received, we observed significantly 
lower levels of Gr-MDSC in comparison to untreat-
ed group. This however, was not true for Mo-MDSC 
as their level in the blood of patients post-surgical 
treatment or after hormonal therapy did not differ 
significantly from the non-treated group. These re-
sults may suggest that surgery or hormonal therapy 
alone have no effect on the blood level of Mo-MDSC 
or these forms of treatment can even induce appear-
ance of Mo-MDSC, as it was shown already for ra-
diotherapy [28]. The study by Koga et al., demon-
strated that prostate cancer patients with increased 
level of Mo-MDSC after the treatment had overall 
Fig. 6. Gr-MDSCs (A) Mo-MDSCs (B) PSA level (C) in healthy control subjects and prostate cancer patients divided in 
four groups depending on the treatment option. PSA normal level is indicated
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worse survival [29]. Similar pattern, documenting 
an increased level of Mo-MDSC after therapy we ob-
served also when analyzed blood from patients with 
colorectal cancer receiving surgery (manuscript in 
preparation). In case of prostate cancer, only patients 
receiving a combined treatment showed the level 
of Mo-MDSC comparable to this observed in a group 
of healthy donors and significantly lower than in 
a group before any treatment or receiving surgical 
or hormonal therapy alone. Although the others in-
dicated a correlation between the level of MDSC and 
the clinical stage of prostate cancer patients [30], in 
our studies we did not observe such a connection. 
The level of Gr-MDSC or even Mo-MDSC was in-
dependent of the tumor grading and clinical stage, 
most likely due to the relatively small study groups. 
Similar pattern we observed in respect to the PSA 
level. In this case all patients presented the PSA level 
higher than the normal range, however no correla-
tion between this parameter and the clinical stage or 
tumor grading was detected.
Up to now there have been no studies on the level 
of MDSC populations in the blood of prostate cancer 
patients in respect to different forms of treatment. 
Although, our work has a preliminary character and 
the groups of patients were small, it suggests that sin-
gle method of treatment is not sufficient for the elim-
ination of circulating MDSC, especially of monocyte 
origin. If this, however should be replaced by a com-
bined therapy, further prolonged observations, in-
cluding patients’ survival analysis is required.
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